← All trials
NCT03997968
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2019
- Primary completion
- Sep 30, 2021
- Completion date
- Oct 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 165
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cyteir Therapeutics, Inc.Lead sponsor
- Cyteir Therapeutics, Inc.Study director
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Breast Neoplasms
- Head and Neck Neoplasms
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Sarcoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Mantle-Cell
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.